"With first sales expected imminently, this is a milestone for CellPlan and the Group as a whole."
Showing 25 of 1743
The first system LIGHT system will be installed in its Harley Street facility, which is scheduled to be ready for installation by the first half of 2019
The cash and shares acquisition of Ecuphar - a European animal health company - will see the enlarged group have direct sales organisations in seven countries, against just the one currently for Animalcare.
The Republicans are looking to repeal Obamacare as well as trying to ease regulatory pressures in the industry
The FTSE 100-listed drugmaker said, following the approval, it expects the drug to become available in the US in the third quarter of this year.
Having reached the recruitment mid-point for coagulant PeproStat, it expects to deliver the first data from the study by the fourth-quarter of this year, rather than in the first three months of 2018
The US Food & Drug Administration (FDA) green light means its human retinal progenitor cells (hRPC) can be frozen for shipping and storage and thawed at the point of use.
This ability to turn tumours ‘hot’ is seen as key to help a person’s immune system fight their cancer.
BTG said it has created the only treatment proven to significantly reduce the signs and symptoms of post-thrombotic syndrome
The Parsortix system, which is used to harvest circulating tumour cells from the blood stream associated with cancer, helped researchers from the Queen Mary University of London's Barts Cancer Institute find two rare cells.
House broker finnCap believes HLH experienced interest in the product above the levels it had been expecting
“These funds will enable us to reach and go beyond the upcoming key inflection points”
VAL-401 is being developed jointly by ValiRx and Tangent Reprofiling as part of the pair’s ValiSeek collaboration.
For the three months to April 30, the biotech firm reported a pre-tax loss of £5.96mln, down from last year’s £6.37mln loss, on revenue of £1.72mln, compared to nil in the prior year
The broker has been bullish on the sector since November’s US elections, in which time the sector has advanced 20%, or 12% in relative terms.
The £225,000 order is from HuanZhong Biotech, Concepta’s partner in China
In results for the year to March 31 2017, the AIM-listed firm saw its revenue increase by 89% to £18.7mln, up from £9.9mln a year earlier, with underlying revenue growth at 41%
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
The deal is a continuation of the work Midatech has already carried out in the brain cancer space
Midatech has three lead R&D programmes: a carcinoid syndrome treatment; a liver cancer drug; and a brain cancer therapy
The Swiss firm will pay AstraZeneca US$200mln upon completion of the deal, and AstraZeneca will also receive up to an additional $102mln in future milestone payments
It was only a small-scale, early stage trial but Nanobiotix thinks NBTXR3 has the potential to “play a key role in the treatment of head and neck cancer”
David Roblin, Summit’s president of research & development, said: "These positive preclinical data presented at ASM Microbe highlight the potency of ridinilazole against a wide range of CDI clinical isolates from patients with CDI”
With US licensee driving the Phase 1 trials of Sareum's lead candidate, SRA737, the focus moves to TYK2, a compound that is targeting psoriasis, rheumatoid arthritis, and other autoimmune disorders
There were also promising readouts from a prostate cancer trial and an early-stage ovarian cancer study